Gland Pharma CDMO deals target $100m run-rate by 2029

What Gland Pharma announced and why it matters

Gland Pharma Limited has disclosed two separate contract manufacturing developments that expand its CDMO footprint across sterile injectables and sterile active pharmaceutical ingredients (APIs). The first is a strategic Manufacturing and Supply Agreement (MSA) with an undisclosed leading global pharmaceutical company for a portfolio of sterile injectable products. The second is a long-term strategic CDMO partnership with Neuland Laboratories Limited to create additional sterile API manufacturing capacity at Gland Pharma’s JNPC facility in Visakhapatnam.

Together, the announcements signal an effort to deepen Gland Pharma’s role beyond routine manufacturing into end-to-end development and supply, including technology transfer, validation, and long-term commercial production. The MSA, in particular, provides a quantified long-term revenue opportunity, but with revenues expected to start only from calendar year 2029.

Deal 1: Manufacturing and Supply Agreement for 55 SKUs

Gland Pharma said it has entered into a strategic MSA with a leading global pharmaceutical company to manufacture and supply a portfolio of sterile injectable products for global markets. The product basket covers 55 sterile injectable SKUs, including oncology products as well as non-oncology products.

Under the arrangement, Gland Pharma is positioned as an integrated end-to-end partner under a full-service CDMO model. The scope spans technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply. This is important because it ties manufacturing work to earlier-stage technical activities, which typically increases project stickiness once products reach commercialization.

End-to-end CDMO scope: what is included

The company described the engagement as covering the full chain required to industrialise and supply sterile injectables. That includes technology transfer and process development before scaling up to validation and commercial manufacturing. It also includes long-term supply commitments once the products are commercialised.

This structure matters operationally because sterile injectables involve complex aseptic manufacturing requirements and regulatory expectations. By explicitly placing technology transfer and validation in the scope, the agreement implies a multi-year execution phase before steady-state supply begins.

Revenue potential: USD 90–100 million annualised, starting 2029

Gland Pharma estimated annualised revenue potential of USD 90–100 million once all products under the MSA are commercialised. The company also stated that technology transfer activities are planned for completion within two years.

However, revenues from this partnership are anticipated to commence only from calendar year 2029. That timeline indicates that near-term financial impact is limited, while the key value is longer-term visibility tied to commercial launches over time.

Counterparty remains undisclosed

The counterparty in the MSA is not named due to confidentiality obligations. Gland Pharma identified it only as one of the leading global pharmaceutical companies.

While this limits external verification of pipeline specifics, the company has provided concrete details on the product scope (55 SKUs), therapeutic mix (oncology and non-oncology), and the revenue ramp timeline (2029 commencement), which are the core economic and operational markers of the deal.

Deal 2: Gland Pharma and Neuland tie up for sterile APIs

Separately, Gland Pharma and Neuland Laboratories announced on August 5, 2026 a long-term strategic CDMO partnership for complex sterile APIs. The partnership is focused on manufacturing sterile APIs for microparticle depot products, and is intended to offer an integrated CDMO solution covering API development, scale-up, regulatory support, and commercial manufacturing.

Under the agreement, Gland Pharma will establish a dedicated sterile API manufacturing suite at its JNPC (Jawaharlal Nehru Pharma City) facility in Visakhapatnam, India, to support Neuland’s sterile API requirements for global drugmakers. The suite is expected to add around 1,400 kg of annual capacity and provide flexibility to manufacture multiple sterile products.

Facility build-out, investment, and guarantees

The manufacturing suite is planned to be designed, constructed, and operated to cGMP, US FDA, and EU regulatory standards, reflecting the target markets served by global customers. The expansion is expected to be completed within 6–7 months.

The project requires an investment of ₹39.8 crores (including GST), which is expected to be financed through internal accruals. To secure the obligations under the associated Loan Licence Agreement, Neuland executed an irrevocable corporate guarantee of ₹40 crores in favour of Gland Pharma. The companies also noted that the promoter group has no interest in the transaction and that it was executed at arm’s length.

Why these deals fit the sterile manufacturing theme

Both announcements are linked by a common theme: expanding capabilities and long-term engagement in sterile products. The MSA is aimed at sterile finished-dose injectables across oncology and non-oncology, with technology transfers and commercial supply aligned to a multi-year roadmap.

The Neuland partnership extends the sterile story upstream into sterile APIs, particularly for microparticle depot products, and adds a quantified capacity addition at Gland’s Visakhapatnam site. It also formalises a combined development-to-commercialisation offer, where Neuland’s complex API expertise is paired with Gland’s aseptic manufacturing infrastructure and compliance track record.

Key facts at a glance

Market impact and what investors will track

For investors following Gland Pharma, the MSA provides a clear long-term revenue marker but also sets expectations that the cash flow contribution is back-ended, with revenue commencement expected from 2029. The key execution checkpoint is completion of technology transfer activities within two years, followed by validation and commercial readiness.

In the Neuland partnership, the measurable near-term element is capacity build-out at JNPC in Visakhapatnam and the planned completion timeframe of 6–7 months. The disclosed investment amount and the corporate guarantee provide additional clarity on the financial structure supporting the project, although no revenue figure is provided for this partnership in the details shared.

Conclusion

Gland Pharma’s announcements outline two distinct CDMO tracks: a 55-SKU sterile injectables manufacturing and supply program with an estimated USD 90–100 million annualised potential once commercialised, and a sterile API capacity expansion with Neuland at the Visakhapatnam JNPC facility adding about 1,400 kg per year. The next milestones to watch are the progress of technology transfer under the MSA over the next two years and the completion of the sterile API suite within the stated 6–7 month window, with the injectables revenue expected to begin from calendar year 2029.